The FDA approved the lazertinib+amivantamab therapy on Aug 20. A monumental case for a local anti-cancer drug to get FDA approval for commercial use in the US
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.